Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions

Human Gene Therapy
Frank SchwenterP Aebischer

Abstract

Allogeneic cells are the most attractive source for cell transplantation, as the use of xenogeneic cells is hampered by safety concerns and the use of autologous cells involves practical difficulties. The immune rejection of allogeneic cells can be overcome by physical immunoprotection provided by polymer encapsulation. To study the variability of cell and donor sources, we compared different primary human cells as candidates for gene therapy-mediated delivery of human erythropoietin (hEpo). DARC-3.1 fibroblasts, MDX-01 fibroblasts, and ARPE-19 retinal pigment epithelial cells were encapsulated into polyethersulfone hollow fibers and implanted for 1 month in nude mice as well as in immunocompetent and FK506-immunosuppressed mice to test their in vivo resistance, with the assumption that xenogeneic conditions constitute a stringent model for human application. DARC-3.1 fibroblasts showed the best survival, prompting us to evaluate cell lineages from the same donor (DARC-3.2) or another donor (DARC-4.3 and DARC-4.4). With the exception of DARC-4.3, the remaining three lineages showed comparable survival in immunocompetent C3H and DBA/2J mice. DARC-3.1 fibroblasts were retrovirally engineered with hEpo cDNA, reaching a secretion l...Continue Reading

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y DaiI M Verma
Dec 15, 1992·European Journal of Biochemistry·M J Koury, M C Bondurant
Feb 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T D PalmerA D Miller
Jul 20, 1989·The New England Journal of Medicine·J W EschbachJ W Adamson
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·W R OsborneA W Clowes
Apr 1, 1995·The Journal of Clinical Investigation·Y HamamoriL Kedes
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·N NaffakhY Beuzard
Nov 1, 1994·Human Gene Therapy·Y HamamoriL Kedes
Aug 1, 1993·Human Gene Therapy·P L ChangA J Westcott
Feb 1, 1996·Experimental Eye Research·K C DunnL M Hjelmeland
Aug 5, 1997·Proceedings of the National Academy of Sciences of the United States of America·A D KirkS J Knechtle
Aug 1, 1997·The Journal of Investigative Dermatology·S M Page, G G Brownlee
Jan 22, 1998·The Journal of Thoracic and Cardiovascular Surgery·R BraunerL Wu
Jun 1, 1997·American Journal of Ophthalmology·S KusakaY Tano
Apr 16, 1998·Journal of Muscle Research and Cell Motility·S V Brooks
Apr 16, 1998·Anesthesia and Analgesia·J A Rosenthal
Jun 13, 2001·Gene Therapy·B L SchneiderP Aebischer

❮ Previous
Next ❯

Citations

Feb 1, 2008·Heart Failure Reviews·Robert N Foley
Jul 2, 2005·Cancer Biotherapy & Radiopharmaceuticals·Meiqing ShiJim Xiang
Jan 13, 2006·Journal of Vascular Research·Eilat HassonEduardo Mitrani
Mar 4, 2014·Advanced Drug Delivery Reviews·Clark K Colton
Nov 26, 2013·Advanced Drug Delivery Reviews·Paul de VosMarijke M Faas
May 27, 2015·International Journal of Molecular Sciences·Aurélien LathuilièreBernard L Schneider
Jan 19, 2006·The Journal of Investigative Dermatology·Yunyuan LiAziz Ghahary
Sep 5, 2006·Seminars in Nephrology·Iain C Macdougall
Dec 8, 2009·Medicinal Research Reviews·Ainhoa MuruaJosé Luis Pedraz
Jul 27, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Einat Brill-AlmonNoam Shani
Dec 29, 2017·Advanced Healthcare Materials·Christophe BossUmberto De Marchi
Oct 27, 2010·World Journal of Stem Cells·Shengwen Calvin Li, Jiang F Zhong
Aug 14, 2018·Advanced Healthcare Materials·Clara R CorreiaJoão F Mano
Dec 14, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Iain C Macdougall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.